Nalaganje...
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
PURPOSE: HR+/HER2− aromatase inhibitor (AI)-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the...
Shranjeno v:
| izdano v: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026053/ https://ncbi.nlm.nih.gov/pubmed/29623577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4779-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|